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ABBREVIATIONS  
BMMC:  Bone  Marrow-­derived  Mast  Cell,  FceRI:  Fc  epsilon  Receptor  I,  HAT:  
Histone  Acetyltransferases,  HDAC:  Histone  Deacetylase,  HDACi:  Histone  
Deacetylase  Inhibitor,  PLCg2:  Phospholipase  C  gamma  2,  SCF:  Stem  Cell  Factor,  
TNP-­BSA:  Trinitrophenol-­conjugated  Bovine  Serum  Albumin,  TSA:  Trichostatin  A,  
VPA:  Valproic  Acid  
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ABSTRACT  
Mast  cell  activation  through  the  high-­affinity  IgE  receptor  (FcεRI)  plays  a  central  
role  in  allergic  reactions.  FcεRI-­mediated  activation  triggers  multiple  signaling  
pathways  leading  to  degranulation  and  synthesis  of  different  inflammatory  
mediators.  IgE-­mediated  mast  cell  activation  can  be  modulated  by  different  
molecules,  including  several  drugs.  Herein,  we  investigated  the  immunomodulatory  
activity  of  the  histone  deacetylase  inhibitor  valproic  acid  (VPA)  on  IgE-­mediated  
mast  cell  activation.  To  this  end,  bone  marrow-­derived  mast  cells  (BMMC)  were  
sensitized  with  IgE  and  treated  with  VPA  followed  by  FceRI  crosslinking.  The  
results  indicated  that  VPA  reduced  mast  cell  IgE-­dependent  degranulation  and  
cytokine  release.  VPA  also  induced  a  significant  reduction  in  the  cell  surface  
expression  of  FcεRI  and  CD117,  but  not  other  mast  cell  surface  molecules.  
Interestingly,  VPA  treatment  inhibited  the  phosphorylation  of  PLCγ2,  a  key  
signaling  molecule  involved  in  IgE-­mediated  degranulation  and  cytokine  secretion.  
However,  VPA  did  not  affect  the  phosphorylation  of  other  key  components  of  the  
FceRI  signaling  pathway,  such  as  Syk,  Akt,  ERK1/2,  or  p38.  Altogether,  our  data  
demonstrate  that  VPA  affects  PLCγ2  phosphorylation,  which  in  turn  decreases  IgE-­
mediated  mast  cell  activation.  These  results  suggest  that  VPA  might  be  a  key  
modulator  of  allergic  reactions  and  might  be  a  promising  therapeutic  candidate.  
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INTRODUCTION  
Mast  cells  have  a  wide  distribution  in  diverse  tissues,  including  the  mucosa,  where  
they  display  important  functions  during  tissue  homeostasis  [1].  Mucosal  mast  cells  
reside  in  near  contact  with  the  environment  and  are  crucial  in  the  early  response  to  
pathogens  and  in  the  development  of  allergic  diseases  [2],  which  are  a  serious  and  
growing  health  problem  worldwide  [3].    
  
Mast  cells  originate  from  hematopoiesis,  and  contain  abundant  cytoplasmic  
granules  filled  with  different  chemical  mediators  such  as  histamine,  heparin,  
serotonin,  cytokines,  growth  factors,  chymase  and  tryptase  [4].  During  allergic  
reactions,  mast  cells  are  activated  through  the  cross-­linking  of  Fc  epsilon  receptors  
I  (FcεRI)  by  the  interaction  of  allergens  with  membrane-­bound  IgE,  leading  to  the  
release  of  granules  contents,  and  de  novo  synthesis  and  secretion  of  other  
inflammatory  mediators  such  as  prostaglandins,  leukotrienes  and  cytokines.  Thus,  
the  chronic  activation  of  mast  cells  contributes  to  the  pathophysiology  of  various  
allergic  diseases  through  the  induction  of  sustained  inflammatory  environment  
leading  to  tissue  damage  [5].  Therefore,  the  development  of  new  therapies  that  
enable  the  regulation  of  mast  cell  activation  is  a  priority  in  allergic  diseases.  In  this  
line,  several  approaches  are  under  investigation,  including  the  targeting  of  
activating  mast  cell-­surface  receptors  or  cell-­signaling  molecules  that  participate  in  
FceRI  mediated-­activation  as  well  as  the  engagement  of  mast  cell  inhibitory  
receptors  [6].  
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Valproic  acid  (VPA)  is  a  short-­chain  fatty  acid  which  is  derived  from  valeric  acid,  
obtained  from  root  extracts  of  valerian  flower  plant  (Valeriana  officinalis).  VPA  has  
a  broad  spectrum  of  actions  and  it  is  commonly  used  in  anticonvulsant  therapy  and  
as  a  mood  stabilizer  [7].  Research  into  the  mechanism  of  action  has  shown  that  
VPA  acts  as  an  histone  deacetylase  inhibitor  (HDACi),  reverting  epigenetically  
silenced  genes  in  tumor  cells,  a  property  that  has  been  harnessed  to  design  new  
therapeutic  approaches  for  cancer  [8,  9].  Recent  studies  have  demonstrated  that,  
through  regulation  of  key  cell  signaling  molecules,  VPA  can  also  modulate  the  
functional  activity  of  innate  and  adaptive  immune  cells  including  macrophages,  
dendritic  cells,  neutrophils,  NK  cells,  B  and  T  lymphocytes  [10].  Considering  that  
IgE-­mediated  mast  cell  activation  plays  a  crucial  role  in  allergic  diseases  and  that  
VPA  interferes  with  cell  signaling  in  several  cells  of  the  immune  response,  this  
study  was  conducted  to  investigate  whether  VPA  could  modulate  the  FceRI-­
mediated  mast  cell  activation.  
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MATERIAL  AND  METHODS  
Valproic  acid  
An  injectable  solution  of  sodium  valproic  acid  (Depakene®)  was  obtained  from  
Hospira  Inc.  (Pfizer;;  Kansas,  USA).  
  
Cell  culture  
Bone  marrow-­derived  mast  cells  (BMMC)  are  commonly  obtained  by  culturing  with  
combinations  of  IL-­3  and  SCF.  However,  as  reports  have  shown  that  chronic  
exposure  to  SCF  results  in  attenuated  FceRI  signaling  and  degranulation  of  mast  
cells,  here  we  have  used  cultures  of  bone  marrow  from  6-­8  week-­old  C57BL/6  
female  mice  in  the  presence  of  IL-­3  alone,  as  described  [11,  12].  Mast  cell  purity  
was  ≥95%  as  determined  by  flow  cytometry  after  staining  of  CD117  (clone:  2B8,  
BioLegend,  USA)  and  FcεRI  (clone:  MAR-­1,  BioLegend,  USA).  The  protocol  to  
derive  mast  cells  from  mouse  bone  marrow  was  reviewed  and  approved  by  the  
Committee  for  Ethics  in  Research,  ENCB-­IPN.  
  
Cell  viability  
BMMC  viability  was  assessed  by  flow  cytometry  following  staining  of  cells  with  
Annexin  V  and  propidium  iodide.  Briefly,  BMMC  were  incubated  with  VPA  for  18  h,  
and  stained  with  APC-­Annexin  V  (BioLegend,  San  Diego,  CA,  USA)  and  propidium  
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iodide  (eBioscience,  Waltham,  MA,  USA).  Viable  cells  were  considered  as  double  
negative  for  both  markers.  
  
IgE-­mediated  mast  cell  activation  
To  evaluate  mast  cell  degranulation,  we  followed  previously  described  methods  
[13,  14].  Briefly,  1x106  BMMC  were  sensitized  with  2  µg/ml  monoclonal  IgE  a-­
trinitrophenyl  (clone:  MEA-­36,  BioLegend,  San  Diego,  CA,  USA)  for  18  h  at  37˚C.  
For  VPA  treatment,  cells  were  incubated  with  VPA  during  sensitization.  Then,  
BMMCs  were  washed  and  activated  with  100  ng/ml  TNP-­BSA  (Santa  Cruz  
Biotechnology,  Dallas,  TX,  USA)  for  1  hour  and  then  stained  with  anti-­CD107a  
(clone:  1D4B  BioLegend,  USA).    
  
Cytokine  quantification  
BMMC  were  cultured  with  or  without  2mM  VPA  during  the  sensitization  period.  
Cells  were  then  stimulated  with  TNP-­BSA  and  supernatants  were  collected  after  24  
h  of  culture.  Release  of  IL-­6,  TNF-­α  (BioLegend,  San  Diego,  CA,  USA)  and  IL-­13  
(eBioscience,  Waltham,  MA,  USA)  was  measured  by  ELISA  according  to  the  
manufacturer’s  instructions.  
  
Assessment  of  mast  cell  surface  receptors  expression  
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BMMC  were  incubated  with  1  mM  VPA  for  24  h  and  then  stained  with  anti-­  FceRI  
(BioLegend,  San  Diego,  CA,  USA),  anti-­CD45  (clone:  30-­F11,  BD  Biosciences,  
Franklin  Lanes,  NJ,  USA),  anti-­CD44  (clone:  IM7,  eBioscience,  Waltham,  NJ,  USA)  
and  anti-­CD117  (BioLegend,  San  Diego,  CA,  USA).    
  
Evaluation  of  phosphorylated  proteins  
BMMC  were  sensitized  with  IgE,  incubated  with  or  without  VPA  for  18  h,  and  then  
activated  with  100  ng/mL  TNP-­BSA.  After  5  min  of  activation,  cells  were  preserved  
with  Fixation  Buffer  (BD  Biosciences,  Franklin  Lanes,  NJ,  USA)  and  permeabilized  
with  Perm  Buffer  III  (BD  Biosciences,  Franklin  Lanes,  NJ,  USA)  or  Perm  Buffer  IV  
(BD  Biosciences,  Franklin  Lanes,  NJ,  USA)  for  phospho  (p)-­p38  staining.  
Subsequently,  cells  were  stained  with  antibodies  to  p-­ERK1/2  (clone:  20A),  
p-­Syk  (clone:  l120-­722),  p-­PLC-­𝛾2  (clone:  K86-­689.37),  p-­Akt  (clone:  M89-­61),  or  
isotypes  controls.  For  p-­p38  (clone:  36/p38),  cells  were  chased  after  10  min,  
permeabilized  with  Perm  Buffer  IV  (BD  Biosciences,  Franklin  Lanes,  NJ,  USA)  and  
stained  as  described  above.  All  antibodies  were  from  BD  Biosciences  Franklin  
Lanes,  NJ,  USA.  
  
Flow  Cytometry  
All  cell  samples  stained  with  fluorochrome-­conjugated  antibodies  against  cell  
surface  markers  and  intracellular  phosphorylated  proteins  were  acquired  using  
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FACSCalibur  or  FACS  Aria  III  cytometers  (BD  Biosciences,  Franklin  Lanes,  NJ,  
USA)  and  analyzed  with  FlowJo  7.1  software.  
  
Data  analysis  and  statistics  
All  data  were  analyzed  using  GraphPad  Prism  V6  Software.  Data  are  presented  as  
mean  ±  SD  of  at  least  3  independent  experiments,  unless  otherwise  stated.  
Statistical  significance  was  determined  using  ANOVA  with  Tukey's  Multiple  
Comparison  Test  or  t-­student  test  in  the  case  of  two  groups.  Kruskal-­Wallis  test  
with  Dunnett's  Multiple  Comparison  test  was  used  with  normalized  data.  A  p-­value  
<0.05  was  considered  statically  significant.  
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RESULTS  AND  DISCUSSION    
Low  VPA  concentrations  do  not  affect  mast  cell  viability  
VPAcan  inhibit  the  activation  of  several  cell  populations  of  the  immune  response  
[10].  However,  VPA  also  has  cytotoxic  effects  in  some  cancer  cell  lines,  a  feature  
that  has  been  considered  beneficial  in  the  treatment  of  cancer  [8].  
Furthermore,VPAshows  a  concentration-­dependent  effect  on  the  growth  and  cell  
viability  of  human  mast  cell  line  HMC1.2  [15].  To  discard  the  possibility  of  any  
modulatory  effect  of  VPA  on  mast  cells  being  due  to  their  cytotoxic  effect,  we  
established  a  VPA  concentration  that  did  not  affect  BMMC  viability.  To  this  end,  
BMMC  were  incubated  with  VPA  for  18  h  at  concentrations  that  have  been  shown  
an  effect  on  activation  in  other  immune  cell  populations  [16,17].    VPA  did  not  
induce  a  significant  change  in  mast  cell  size  or  complexity,  except  at  5  mM  which  
induced  a  slight  increase  in  cell  size  (Supplemental.  Fig.  1).  BMMC  treated  with  5  
or  10  mM  VPA  showed  a  significant  decrease  in  their  viability  when  compared  with  
untreated  cells.  In  contrast,  1  or  2  mM  VPA  did  not  significantly  affect  the  viability  
of  BMMC  (Figs.  1B  and  C).  These  VPA  concentrations  were  used  in  subsequent  
experiments.  
  
VPA  diminishes  IgE-­mediated  mast  cell  degranulation  
Previous  reports  indicate  that  different  HDACi  can  interfere  with  IgE-­mediated  mast  
cell  degranulation  [18,19].  To  determine  the  ability  of  VPA  to  affect  mast  cell  
degranulation,  BMMC  were  treated  with  VPA,  sensitized  with  IgE  for  18  h,  and  
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followed  by  degranulation  induction  by  Fc𝜀RI  cross-­linking  with  TNP-­BSA.  VPA-­
treated  BMMC  showed  a  significant  reduction  in  the  percentage  of  degranulated  
cells  after  Fc𝜀RI  cross-­linking  as  evidenced  by  the  expression  of  CD107a  on  the  
cell  surface  of  BMMC  (Figs.  1D  and  E).  Interestingly,  VPA  alone  was  unable  to  
induce  mast  cell  degranulation  (Supplemental.  Fig.  2A).  This  finding  shows  that  the  
HDACi  VPA  is  an  inhibitor  of  IgE-­mediated  mast  cell  degranulation,  like  other  
HDACi  such  as  MGCD0103  and  Trichostatin  A  (TSA)  [18,19].  VPA  also  inhibits  
degranulation  in  other  immune  cells,  such  as  NK  cells,  in  which  their  cytotoxicity  
against  tumoral  cells  is  restrained.16,20  This  reduction  in  NK  cell-­mediated  
cytotoxicity  by  VPA  was  associated  with  the  inhibition  of  STAT3  phosphorylation,  a  
molecule  that  is  key  in  NK  cell  signaling  [20].  
  
VPA  decreases  TNF-­a,  IL-­6,  and  IL-­13  release  during  Ig-­E  mediated  mast  cell  
activation    
In  addition  to  trigger  degranulation,  Fc𝜀RI  cross-­linking  also  promotes  mast  cell  
production  of  allergy-­related  proinflammatory  cytokines  such  as  TNF-­𝛼,  IL-­6,  and  
IL-­13,  which  contribute  to  the  pathogenesis  of  allergic  diseases  [5].  Therefore,  we  
investigated  whether  VPA  could  affected  the  release  of  these  cytokines  in  mast  
cells  activated  through  Fc𝜀RI  cross-­linking.  We  observed  that  while  treatment  of  
BMMC  with  VPA  alone,  or  in  the  presence  of  IgE,  was  unable  to  induce  IL-­6  
release  (Supplemental.  Fig.  2B),  VPA  diminished  the  secretion  of  the  3  cytokines  
after  FC𝜀RI  cross-­linking  when  compared  with  untreated  BMMC  (Figs.  1F–H).  
These  results  indicate  that  VPA  can  interfere  with  cytokine  production  after  mast  
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cell  activation  through  Fc𝜀RI,  as  has  been  observed  with  other  HDACi,  such  as  
sodium  butyrate,21  and  TSA.19  Furthermore,  VPA  inhibits  cytokine  production  in  
several  cells  of  the  immune  response,  such  as  monocytes,  macrophages,  dendritic  
cells,  and  CD4+  T  cells,  mainly  through  interfering  with  the  intracellular  cell  
signaling  pathways  that  leads  to  cytokine  production  [10].  
 
  
Expression  of  FcεRI  is  reduced  in  VPA-­treated  mast  cells    
VPA  inhibits  activation  of  immune  cells  by  down-­modulating  the  expression  of  
activating  receptors.  For  instance,  VPA  reduces  the  expression  of  NKG2D  on  NK  
cells  [20]  scavenger  receptors  and  several  TLRs  on  macrophages  [22]  and  
costimulatory  molecules  on  plasmacytoid  dendritic  cells  [23].  Based  on  these  
findings,  we  evaluated  whether  VPA  could  affect  Fc𝜀RI  expression  on  mast  cells.  
We  observed  that  VPA  induced  an  average  80%  reduction  in  the  cell  surface  
expression  of  Fc𝜀RI  on  mast  cells  (Fig.  2A).  To  address  whether  VPA  affected  
other  activation  receptors  on  mast  cells,  we  evaluated  the  expression  of  CD117,  
the  SCF  receptor  that  is  involved  in  mast  cell  activation  and  proliferation  [24].  We  
noticed  that  VPA  also  reduced  CD117  expression  on  mast  cells,  but  to  a  lesser  
extent  (Fig  2B).  To  discern  if  the  inhibitory  effect  of  VPA  was  generalized  on  cell  
surface  receptors,  we  measured  the  expression  of  CD44  and  CD45  on  mast  cells.  
CD44  is  a  receptor  for  hyaluronan  and  is  a  crucial  molecule  in  the  regulation  of  
proliferation  and  differentiation  of  dermal  mast  cells  [25],  whereas  CD45  is  a  
receptor  involved  in  fine-­tuning  the  signaling  pathways  leading  to  mast  cell  
activation  [26].  Remarkably,  VPA  did  not  to  affect  the  expression  of  CD44  and  
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CD45  on  mast  cells  (Figs.  2C  and  D).  Finally,  we  evaluated  the  kinetics  of  Fc𝜀RI  
expression  on  mast  cells  after  VPA  treatment.  We  observed  that  VPA  treatment  
induced  a  reduction  in  Fc𝜀RI  cell  surface  expression,  which  was  significative  after  
18  h  of  treatment  (Fig.  2E).  This  result  is  consistent  with  a  previous  report  showing  
that  the  HDACi  TSA  also  affected  Fc𝜀RI  expression  on  mast  cells  depending  on  
the  time  of  exposure  [19].  Interestingly,  VPA  exposure  had  a  differential  effect  on  
the  expression  of  other  mast  cell  receptors.  This  differential  effect  has  also  been  
observed  in  macrophages  exposed  to  the  HDACi  TSA,  which  diminished  the  
expression  of  IL-­12p40  but  increased  the  levels  of  PAI-­1  [27].  Consistent  with  this,  
VPA  has  also  shown  a  differential  effect  on  the  expression  of  receptors  in  tumor  
cells,  promoting  an  increase  in  MICA/B  andULBP2,  but  did  not  affect  the  
expression  of  ULBP1,  3,  and  4  [28].  Thus,  these  findings  indicate  that  VPA  
interferes  with  the  expression  of  the  activating  mast  cell  receptors  Fc𝜀RI  and  
CD117,  whereas  the  expression  of  CD44  and  CD45  are  not  affected.  
  
3.5  VPA  decreases  phosphorylated  PLC𝜸  2  in  mast  cells  stimulated  via  Fc𝜺RI  
  
Because  VPA  diminished  the  expression  of  Fc𝜀RI,  we  next  evaluated  if  VPA  
treatment  was  affecting  the  intracellular  signaling  pathways  of  this  receptor  in  mast  
cells.  To  determine  optimal  time  points  for  evaluation  of  the  phosphorylation  of  key  
molecules  in  mast  cell  signaling,  a  time-­course  of  protein  phosphorylation  was  
performed  after  Fc𝜀RI  cross-­linking  (Supplemental.  Fig.  3).  From  this  analysis,  we  
decided  to  analyze  protein  phosphorylation  after  5–10  min  of  activation.  The  initial  
signaling  following  Fc𝜀RI  cross-­linking  is  mainly  dependent  on  the  activation  of  the  
tyrosine  kinases  Lyn  and  Syk.  This  activation  results  in  the  phosphorylation  of  Syk,  
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which  is  a  critical  step  for  the  downstream  propagation  of  signals  [29].  
Unexpectedly,  Syk  phosphorylation  was  unaffected  by  VPA  in  Fc𝜀RI-­activated  
mast  cells  (Fig.  3A).  Next,  we  evaluated  the  effect  of  VPA  on  phosphorylation  of  
the  serine  threonine  kinase  AKT,  which  is  an  important  signaling  molecule  for  
cytokine  production  during  IgE-­mediated  mast  cell  activation  [30].  We  noticed  that  
VPA  did  not  affect  the  levels  of  p-­Akt  when  compared  with  untreated  mast  cells  
(Fig.  3B).  Besides,  the  MAP  kinase  pathway  also  plays  a  crucial  role  during  IgE-­
mediated  cytokine  production  by  mast  cells  [31].  Thus,  for  a  general  overview  of  
the  MAPK  pathway,  we  evaluated  the  effect  of  VPA  on  the  phosphorylation  of  
ERK1/2  and  p38  in  IgE-­activated  mast  cells.  We  observed  that  neither  the  ERK1/2  
nor  the  p38  phosphorylation  status  were  affected  by  VPA  treatment  (Figs.  3C  and  
D).  
Fc𝜀RI-­dependent  mast  cell  degranulation  and  cytokine  secretion  are  also  regulated  
by  complementary  signaling  pathways,  1  of  which  involves  phospholipase  C𝛾2  
(PLC𝛾2)  [32].  Interestingly,  mast  cells  treated  with  VPA  showed  a  significant  
reduction  in  phosphorylated  PLC𝛾2  when  compared  with  untreated  cells  (Fig.  3E).  
Remarkably,  previous  reports  have  demonstrated  that  PLC-­𝛾2-­deficient  mast  cells  
show  a  reduction  in  their  degranulation,  but  the  cell  signaling  through  ERK,  JNK,  
and  p38  are  unaltered  [32],  as  we  also  observed  in  our  model  with  VPA.  Taken  as  
a  whole,  our  results  indicate  that  VPA  diminishes  IgE-­mediated  mast  cell  
degranulation  and  cytokine  secretion  by  impairing  the  cell  signaling  mediated  by  
PLC𝛾2.  
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These  results  show  that  the  immunomodulatory  ability  of  VPA  can  be  extended  to  
mast  cells,  regulating  the  IgE-­mediated  activation  of  this  cell  population.  
Interestingly,  although  VPA  was  able  to  downmodulate  the  expression  of  cell  
surface  activating  receptors  on  mast  cells,  in  particular  Fc𝜀RI,  this  event  did  not  
affect  the  early  cell  signaling  pathway  triggered  by  the  cross-­linking  of  the  bound  
IgE  in  mast  cells,  indicating  that  the  few  Fc𝜀RI  expressed  on  the  mast  cell  surface  
were  still  able  to  start  signaling  pathways  leading  to  mast  cell  activation.  
Furthermore,  the  immunomodulatory  effect  of  VPA  was  associated  with  a  
diminished  activation  of  PLC-­𝛾2  as  evidenced  by  its  decreased  phosphorylation  
state.  This  result  reinforces  the  notion  that  VPA  has  the  ability  to  interfere  with  the  
activation  of  key  molecules  during  cell  signaling  of  immune  cells.  For  instance,  
VPA  interferes  with  the  phosphorylation  of  MDM2,  Akt,  PI3K,  and  NF-­𝜅B  in  
macrophages  activated  with  LPS,  whereas  in  NK  cells,  VPA  reduces  STAT3  and  
STAT5  phosphorylation  [10].  
To  our  knowledge,  this  is  the  first  evidence  of  PLC𝛾2  targeting  
by  VPA  in  immune  cells.  PLC  usually  hydrolyzes  phosphatidylinositol  
(4,5)-­bisphosphate  into  diacylglycerol  and  inositol  1,4,5-­triphosphate,  
which  is  crucial  for  the  activation  of  PKC  and  the  increase  of  intracellular  
Ca2+.33  PLC𝛾  has  2  isoforms,  PLC-­𝛾1,  which  is  expressed  in  several  cell  
lineages,  and  PLC𝛾2,  which  is  expressed  in  hematopoietic  cells  [33].  PLC𝛾2  plays  
a  critical  role  during  the  activation  of  several  cells  of  the  immune  response  
including  mast  cells,  macrophages,  NK  cells,  neutrophils,  and  B  lymphocytes  [33].  
So,  it  is  tempting  to  speculate  that  alterations  on  the  activation  of  these  cell  
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populations  by  VPA  could  also  be  related  to  the  inhibition  of  PLC𝛾2,  although  
further  studies  are  needed.  
The  mechanism  by  which  VPA  alters  the  cell  signaling  of  immune  cells  is  unclear;;  
although  previous  reports  indicate  that  VPA  attenuates  phospholipid  cell  signaling  
by  an  unknown  mechanism  [34].  It  is  hypothesized  that  some  HDACi  could  affect  
cell  signaling  through  the  epigenetic  regulation  of  key  molecules  [19].  Because  of  
its  action  as  histone  deacetylase  inhibitor,  VPA  is  able  to  increase  acetylation  of  
histones  H2,  H3,  and  H4,  leading  to  modifications  in  gene  expression  [35].  
This  effect  has  been  suggested  for  TSA,  which  attenuates  IgE-­mediated  mast  cell  
activation  by  increasing  the  expression  I-­𝜅B𝛼,  the  inhibitor  of  NF-­𝜅B  [19].  A  second  
possibility  is  that  alteration  in  HDAC  function  by  VPA  can  induce  a  change  in  the  
acetylation  pattern  of  PLC𝛾2,  which  in  turn  would  alter  its  ability  to  be  activated  
through  phosphorylation.  In  this  sense,  it  has  been  shown  that  protein  acetylation  
through  lysine  residues  plays  a  crucial  role  in  different  cellular  functions,  beyond  
epigenetic  regulation  [36].  For  instance,  STAT  proteins,  which  are  crucial  elements  
in  the  cell  signaling  of  several  cytokines,  are  tightly  regulated  by  lysine  acetylation,  
affecting  their  phosphorylation  and  biologic  function.  Interestingly,  STAT  
acetylation  also  depends  on  the  regulation  of  histone  acetytransferases,  HDAC,  
and  sirtuins  [37].  Whether  PLC𝛾2  is  susceptible  to  be  modified  through  acetylation  
is  unknown,  although  in  silico  analysis  with  GPS-­PAIL  predicts  11  potential  
acetylation  sites  (Supplemental.  Table  1)  [38].  Further  work  is  needed  to  ascertain  
whether  lysine  acetylation  plays  a  role  during  PLC𝛾2  activation.  
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Beyond  its  role  in  allergic  reactions,  mast  cells  also  play  a  crucial  role  in  the  innate  
immune  response  against  virus,  bacteria,  fungi,  protozoa,  and  helminths.  Being  
some  of  the  first  cells  to  sense  the  presence  of  pathogens  their  activation  leads  to  
the  induction  of  inflammation  and  triggering  of  microbicidal  mechanisms  that  help  
to  contain  infection  [2,39].  Whether  this  function  is  affected  by  VPA  needs  to  be  
analyzed.  Previous  reports  indicated  that  VPA  can  alter  the  response  of  
macrophages  to  bacterial  pathogens  [10,40].  TLRs  plays  a  crucial  role  in  sensing  
of  different  bacteria,  and  interestingly  PLC𝛾2  regulates  the  signaling  of  TLR-­4  [41],  
suggesting  a  possible  effect  of  VPA  in  TLR  activation  pathway.  
In  conclusion,  our  results  demonstrate  a  new  effect  of  VPA,  which  attenuates  mast  
cell  activation  through  Fc𝜀RI  by  inhibiting  the  activation  of  PLC𝛾2.  We  suggest  that  
VPA  could  have  a  potential  therapeutic  effect  in  allergic  diseases,  but  further  work  
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Figure  legends  
FIGURE  1  Valproic  acid  decreases  IgE-­mediated  mast  cell  activation.  (A)  Bone  
marrow-­derived  mast  cell  purity  as  assessed  by  Fc𝜀RI  and  CD117  expression.  (B)  
Representative  dot-­plots  of  BMMC  exposed  for  18  h  with  different  doses  of  VPA  
and  stained  with  Annexin  V  and  propidium  ioidide  (PI).  Bottom  right  panel  shows  a  
positive  control  for  cell  death  induction  by  heat.  (C)  Percentage  of  viable  BMMCs  
exposed  to  different  concentrations  of  VPA  for  18  h.  (D)  Effect  of  VPA  on  mast  cell  
degranulation  after  Fc𝜀RI  cross-­linking.  Values  were  normalized  to  the  maximum  
response  observed  in  stimulated  cells  not  treated  with  VPA  and  set  as  1.  (E)  
Representative  flow  cytometry  contour  plots  of  BMMC,  gated  on  FCSH  CD107a+  
cells.  BMMC  were  sensitized  with  anti-­TNP  (𝛼-­TNP)  IgE  and  treated  with  either  1  
or  2mMVPA  for  18  h.  Mast  cell  degranulation  was  induced  with  TNP-­BSA  and  cells  
stained  with  anti-­CD107a.  Kruskal–Wallis  test  with  Dunnett’s  Multiple  Comparison  
Test.  *P  <  0.05,  **P  <  0.01,***P  <  0.001,  n  =  4–5.BMMCwere  sensitized  with  anti-­
TNP  (𝛼-­TNP)  IgE  and  treated  with  either  1  or  2mMVPA  for  18  h.  Mast  cells  were  
activated  with  TNP-­BSA.  After  24  h,  cell  supernatants  were  collected  and  
subjected  to  ELISA  for  detection  of  (F)  TNF-­𝛼,  (G)  IL-­6,  and  (H)  IL-­13.  Data  are  
shown  as  mean  ±  SD.  ANOVA  with  Tukey’s  Multiple  Comparison  Test.  *P  <  0.05,  
**P  <  0.01,  ***P  <  0.001,  n  =  3  
  
FIGURE  2  Valproic  acid  differentially  modulates  the  expression  of  mast  cell  surface  
molecules.  BMMC  were  incubated  with  VPA  during  24  h  and  the  cell  surface  
expression  of  (A)  Fc𝜀RI,  (B)  CD117,  (C)  CD44,  and  (D)  CD45,  was  measured  by  
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flow  cytometry.  Left  panel,  graphs  representing  the  mean  fluorescence  intensity  
(MFI)  of  each  molecule.  Right  panel,  representative  histograms  of  each  cell  surface  
molecule  in  BMMC.  Student  t-­test.  ***P  <  0.001,  **P  <  0.01.  (E)  Kinetics  of  Fc𝜀RI  
expression  on  BMMC  incubated  with  VPA  evaluated  by  flow  cytometry.  Mean  
fluorescence  intensity  (MFI)  values  for  unstimulated  BMCC  were  normalized  and  
set  as  1.  Data  are  shown  as  mean  ±  SD.  Kruskal–Wallis  test  with  Dunnett’s  
Multiple  Comparison  Test.  *P  <  0.05,  n  =  3  
 
  
FIGURE  3  Valproic  acid  decreases  phosphorylated  PLC𝜸2(pPLC𝜸2)  on  mast  cells  
activated  through  Fc𝜺RI.  BMMC  were  sensitized  with  anti-­TNP  (𝛼-­TNP)  IgE  and  
treated  with  1  mM  VPA  for  18  h.  Fc𝜀RI  was  cross-­linkedwith  TNP-­BSA  and  the  
phosphorylation  state  of  molecules  associated  with  Fc𝜀RI-­IgE  signaling  pathway  
was  examined  using  specific    antibodies  to  (A)  p-­Syk,  (B)  p-­Akt,  (C)  p-­ERK1/2,  (D)  
p-­p38,  and  (E)  p-­PLC𝛾2  and  evaluated  by  flow  cytometry.  Left  panel,  graphs  
representing  the  mean  fluorescence  intensity  (MFI)  of  each  phosphoprotein.  Right  
panel,  representative  histograms  of  each  phosphoprotein  in  Fc𝜀RI-­activated  
BMMC.  Data  are  shown  as  mean  ±  SD.  ANOVA  with  Tukey’s  Multiple  Comparison  
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Supplementary  Figure  1.  Valproic  acid  does  not  alter  mast  cell  size  and  
complexity.  BMMCs  were  exposed  to  different  concentrations  of  VPA  for  18  h  and  
analyzed  by  flow  cytometer.  A)  Representative  dot  plots  of  SSC-­‐H  and  FSC-­‐H  are  
shown.  Effect  of  VPA  on  B)  FSC-­‐H  and  C)  SSC-­‐H  of  BMMC.  Data  are  shown  as  
mean  ±  SD.  Kruskal-­‐Wallis  test  with  Dunnett's  Multiple  Comparison  Test.  
**P  <  0.01,  *  P  <  0.05,  n  =  4.  
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Supplementary  Figure  2.  Valproic  acid  does  not  activate  mast  cells.  A)  BMMC  
were  cultured  with  1  mM  or  2  mM  VPA  during  1  h  and  stained  with  anti-­‐CD107a,  
n  =  2.  B)  BMMC  were  cultured  with  VPA  alone  or  sensitized  with  anti-­‐TNP  (α-­‐TNP)  
IgE  in  the  presence  or  absence  of  VPA  for  18  h.  Cell  supernatants  were  collected  
and  IL-­‐6  was  evaluated  by  ELISA.  Data  are  shown  as  mean  ±  SD,  n  =  4.  
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Supplementary  Figure  3.  Kinetic  of  protein  phosphorylation  after  FcεRI  
crosslinking  in  mast  cells  .  BMMCs  were  incubated  with  anti-­‐TNP  (α-­‐TNP)  during  
18  h.  FcεRI  was  crosslinked  with  TNP-­‐BSA.  Protein  phosphorylation  was  evaluated  
for  the  indicated  times  by  intracellular  staining  and  Mean  Fluorescence  Intensity  
(MFI)  is  showed  for  A)  phospho-­‐SYK,  B)  phospho-­‐AKT,  C)  phospho-­‐ERK1/2,  D)  
phospho-­‐P38  and  E)  phospho-­‐PLCγ2.  
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Table  S1.  Prediction  of  acetylation  regions  in  mouse  PLC-­‐γ2  according  to  GPS-­‐
PAIL  [37].  
Position   Peptide   HAT  
15   DTLPEYEKSQIKRAL   EP300  
86   SKDFERAKAVRHKAE   KAT2B  
91   RAKAVRHKAECCFTI   KAT2B  
419   EQQRHMAKVFKEVLG   KAT8  
454   LREKIIIKHKKLGPK   CREBBP  
476   EDKKDEHKPQGELYM   KAT2B  
689   ITFRARGKVKHCRIN   HAT1  
867   VVKAPQGKNQKAFVF   KAT2B  
918   DTKENNMKYWERNQS   KAT2A  
1248   QLQLYQEKCNRRLRE   CREBBP  
1256	   CNRRLREKRVSNSRF	   CREBBP	  
  
  
